Valuation : Vericel Corporation

Market Cap 2.11B 1.81B 1.69B 1.55B 2.92B 201B 2.93B 20.07B 7.84B 102B 7.92B 7.75B 336B P/E 2026 *
74.5x
P/E 2027 * 46.8x
Enterprise Value 2.11B 1.81B 1.69B 1.55B 2.92B 201B 2.93B 20.07B 7.84B 102B 7.92B 7.75B 336B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 5.37x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day-2.97%
1 week-2.21%
Current month-10.40%
1 month-9.14%
3 months+20.16%
6 months+15.41%
Current year+14.36%
1 week 41.16
Extreme 41.16
43.34
1 month 41.16
Extreme 41.16
49.32
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap.
8/12/26 Fiscal year

Director

21,000 0.0411%
8/3/26 Fiscal year

Chief Operating Officer

30,000 0.0587%
7/30/26 Fiscal year

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-2.21%+14.74%+26.79% 2.17B
-0.87%-2.29%+37.61%-2.73% 81.36B
-4.60%+7.09%+468.80%+27.55% 59.75B
-1.21%+3.20%-20.15%-35.88% 59.19B
+0.76%+3.53%+0.08%+36.18% 53.33B
+0.41%+1.84%+10.29%+171.67% 49.09B
+0.19%+3.34%+62.44%-16.23% 32.66B
-0.30%+0.41%+50.57%+100.03% 25.97B
+0.09%+5.08%+18.70%+209.64% 24.39B
+0.78%+0.47%+61.53%+123.40% 16.91B
Average -0.37%+2.19%+70.46%+64.04% 40.48B
Weighted average by Cap. -0.26%+2.37%+87.12%+46.89%

Financials

2026 *2027 *
Net sales 336M 289M 270M 247M 466M 32.11B 467M 3.2B 1.25B 16.18B 1.26B 1.24B 53.56B 393M 337M 316M 289M 545M 37.53B 546M 3.74B 1.46B 18.91B 1.48B 1.44B 62.59B
Net income 29.29M 25.14M 23.54M 21.55M 40.6M 2.8B 40.72M 279M 109M 1.41B 110M 108M 4.67B 47.29M 40.59M 38M 34.8M 65.55M 4.52B 65.74M 450M 176M 2.28B 178M 174M 7.53B
Net Debt - -
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-08-27 US$41.18 -2.97% 533,520
26-08-26 US$42.44 -1.80% 313,606
26-08-25 US$43.22 +2.17% 465,742
26-08-24 US$42.30 -0.89% 812,270
26-08-21 US$42.68 +1.35% 647,128
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
41.18USD
Average target price
60.57USD
Spread / Average Target
+47.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VCEL Stock